🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Hefei
Clinical trial register · China

Clinical Trials in Hefei, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Anhui Provincial Hospital55 Merck Sharp & Dohme LLC36 Anhui Medical University29 AstraZeneca27 Chia Tai Tianqing Pharmaceutical Group Co., Ltd.25
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Hefei

875 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
To Evaluate the Safety and Efficacy of GS1168 Injection in Adult Phenylketonuria
NCT07318909Phenylketonuria (PKU)
Gritgen Therapeutics Co., Ltd.
Phase EARLY_PHASE1
9
Hefei
2027-12-31
Not yet open
Template-Guided Burr-Hole Drainage With Middle Meningeal Artery Coagulation for Chronic Subdural Hematoma
NCT07720687Chronic Subdural Hematoma
The Second Hospital of Anhui Medical University
Not applicable
440
Hefei
2027-01
Not yet open
Frontal vs Parietal Eminence Drainage for Chronic Subdural Hematoma
NCT07731620Chronic Subdural Hematoma
The Second Hospital of Anhui Medical University
Not applicable
440
Hefei, Huai'an, Yangzhou
2027-01
Not yet open
Efficacy and Safety of HN2301 in Patients With Generalized Myasthenia Gravis (MG)
NCT07556120Generalized Myasthenia Gravis
Shenzhen MagicRNA Biotechnology Co., Ltd
Phase 1
6
Hefei
2026-12-31
Not yet open
Safety and Preliminary Efficacy of HN2302 in Patients With Autoimmune Diseases
NCT07523282Autoimmune Disease, Systemic Lupus Erythematosus, Systemic Sclerosis (SSc)
Shenzhen MagicRNA Biotechnology Co., Ltd
Phase 1
12
Hefei
2026-12-31
Not yet open
Study of Efficacy and Safety of FRSW107 in Pediatric Patients With Severe Hemophilia A
NCT06136507Severe Hemophilia A
Hangzhou Gensciences Biopharmaceutical Co., Ltd.
Phase 3
76
Chongqing, Guangzhou, Guizhou, Hangzhou, Hefei, Nanjing, Qingdao, Shenzhen
2026-12-25
Not yet open
Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis
NCT07441408Pulmonary Fibrosis
Bristol-Myers Squibb
Phase 3
2,380
Hefei, Beijing, Shenzhen, Guangzhou, Shenzhen Shi, Zhengzhou, Shijiazhuang, Yichang Shi
2026-12-16
Not yet open
A Study of Orforglipron (LY3502970) in Chinese Participants With Obesity or Overweight and Weight-Related Health Problems
NCT07790861Obesity, Overweight
Eli Lilly and Company
Phase 3
192
Chengdu, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Luoyang Shi, Nanchang
2026-12
Not yet open
A Study to Understand How Nerandomilast Works in People With Active Idiopathic Inflammatory Myopathies
NCT07789015Idiopathic Inflammatory Myopathies
Boehringer Ingelheim
Phase 3
270
Beijing, Chongqing, Dongguan, Guangzhou, Hefei, Luoyang, Nanchang, Nanjing
2026-11-09
Not yet open
Phase III Study of HS-20089 With Bevacizumab in Platinum-Sensitive Recurrent Ovarian Cancer
NCT07821606Platinum-sensitive Recurrent Ovarian Cancer
Hansoh BioMedical R&D Company
Phase 3
460
Hefei, Beijing, Chongqing, Xiamen, Guangzhou, Shaoguan, Nanning, Harbin
2026-11-01
Not yet open
Efficacy of Lipoic Acid on Chronic Ischemic Heart Failure Patients
NCT07725484Heart Failure Due to Coronary Artery Disease
Shanghai Zhongshan Hospital
Phase 3
1,526
Hefei, Fuzhou, Guangzhou, Luoyang, Zhengzhou, Nanjing, Dalian, Xi'an
2026-11-01
Not yet open
Clinical Study on Drug Interactions of Flonoltinib Maleate Tablets
NCT07768111Drug Interaction Research
Chengdu Zenitar Biomedical Technology Co., Ltd
Phase 1
40
Hefei
2026-10-30
Recruiting
Efficacy and Mechanism of Transcranial Temporal Interference Stimulation (tTIS) for Patients With Obsessive-Compulsive Disorders
NCT07805200Obsessive - Compulsive Disorder
Beijing HuiLongGuan Hospital
Not applicable
80
Hefei
2026-10-16
Not yet open
Intratumoral Microbiota and Immune Microenvironment in Prostate Cancer
NCT07818421Prostate Cancer Adenocarcinoma
Anhui Medical University
Observational
100
Hefei
2026-10-01
Not yet open
Spatial Multi-Omics of Perineural Invasion Microenvironment and Prognosis in Prostate Cancer
NCT07818395Prostate Cancer Adenocarcinoma
Anhui Medical University
Observational
120
Hefei
2026-10-01
Not yet open
Perioperative Adebrelimab for Locally Advanced Cervical Cancer
NCT07811375Locally Advanced Cervical Cancer
Anhui Provincial Hospital
Phase 2
35
Hefei
2026-10-01
Not yet open
A Prospective Study Based on Spatial Multi-omics to Predict the Efficacy of ADT Combined With Second-generation Novel Hormonal Agents in Metastatic Hormone-sensitive Prostate Cancer.
NCT07795177Metastatic Hormone-Sensitive Prostate Cancer
Anhui Medical University
Phase 2
40
Hefei
2026-10-01
Not yet open
Clinical Utility of Needle-Based Confocal Laser Endomicroscopy for Peripheral Pulmonary Lesions
NCT07827326Peripheral Pulmonary Lesions
First Affiliated Hospital of Ningbo University
Observational
100
Hefei, Zhejiang, Shanghai
2026-10-01
Not yet open
A Phase 3 Study to Compare the Efficacy of ICP-248 in Combination With Orelabrutinib Versus Pirtobrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL).
NCT07784101Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 3
280
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Shijiazhuang, Zhengzhou, Wuhan
2026-10
Not yet open
Neoadjuvant Endocrine Therapy Combined With Chemotherapy in ER-positive, HER2-negative Stage I-III Breast Cancer
NCT07801898Invasive Breast Cancer (Stage I-III)
The Second Hospital of Anhui Medical University
Phase 2
36
Hefei
2026-09-30
Not yet open
A Phase I Study of Single and Multiple Doses of HS-20136-2 Injection in Healthy or Obese Participants
NCT07716241Obesity
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 1
92
Hefei
2026-09-22
Not yet open
Renal Oxygenation-Guided AKI Reduction Trial
NCT07816640Acute Kidney Injury, Hepatectomy
Chinese PLA General Hospital
Not applicable
1,200
Hefei, Beijing, Chongqing, Lanzhou, Guangzhou, Nanning, Shijiazhuang, Harbin
2026-09-20
Not yet open
Treatment Strategy for Patients With RA-ILD
NCT07643038Rheumatoid Arthritis Associated Interstitial Lung Disease
Chinese SLE Treatment And Research Group
Phase 4
204
Luoyang, Beijing, Changchun, Chongqing, Dalian, Handan, Hangzhou, Hefei
2026-09-20
Recruiting
Oral Zinc Supplementation Combined With Targeted Immunotherapy for Unresectable or Advanced Hepatocellular Carcinoma
NCT07793695Hepatocellular Carcinoma
Anhui Provincial Hospital
Phase 2
60
Hefei
2026-09-16
Not yet open
Real-World Evaluation of Recombinant Human Prourokinase for Acute Ischemic Stroke Within 4.5 Hours
NCT07787325Acute Ischemic Stroke
The First Affiliated Hospital of Anhui Medical University
Observational
3,000
Hefei
2026-09-11
Recruiting
Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
NCT07687459Idiopathic Pulmonary Fibrosis
InSilico Medicine Hong Kong Limited
Phase 3
320
Hefei, Beijing, Fuzhou, Xiamen, Guangzhou, Nanning, Haikou, Shijiazhuang
2026-09-09
Not yet open
A Study to Evaluate the Safety, Tolerability, PK and Preliminary Efficacy of HX15001 Combined With Etrasimod in Moderate-severe Ulcerative Colitis
NCT07768254Colitis, Ulcerative
Helixon Biotechnology (Suzhou) Co., Ltd
Phase 1
32
Hefei
2026-09-09
Not yet open
A Trial of Inebilizumab in Participants With Autoimmune Hepatitis
NCT07598825Autoimmune Hepatitis, AIH
Amgen
Phase 3
180
Hefei, Beijing, Zhengzhou, Shanghai
2026-09-07
Not yet open
A Study of T-DXd in AI-Assessed HER2-Ultralow Metastatic Breast Cancer
NCT07782086Breast Cancer
Shuangyue Liu
Not applicable
30
Hefei, Beijing, Nanjing, Xuzhou, Dalian, Shanghai, Xi’an, Chengdu
2026-09-07
Not yet open
Intravenous Recombinant Human Prourokinase for Acute Medium Vessel Occlusion 4.5-24 Hours After Ischemic Stroke
NCT07776873Acute Ischemic Stroke
The First Affiliated Hospital of Anhui Medical University
Phase 3
616
Hefei
2026-09-06
Not yet open
Pharmacokinetic Characteristics, Safety, and Immunogenicity of HLX29 Compared With HLX11
NCT07776132Health Adult Subjects
Shanghai Henlius Biotech
Phase 1
60
Hefei
2026-09-05
Active, closed
A Pharmacokinetic Study of HDM1005 Injection at Different Injection Sites
NCT07828197Overweight and/or Obesity, Healthy Participants
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase 1
135
Hefei
2026-09-03
Not yet open
A Study of ATG-022 Compared With Investigator's Choice of Treatment in Claudin 18.2-Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
NCT07795346Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Antengene Biologics Limited
Phase 3
380
Bengbu, Hefei, Beijing, Chongqi, Fuzhou, Lanzhou, Wuwei, Guangzhou
2026-09-01
Not yet open
Pre-hepatectomy Rehabilitation in Obese MASLD-Complicated Living Liver Donors With Mazdutide (PRIME)
NCT07718126Metabolic Dysfunction-Associated Steatohepatitis, Hepatic Steatosis, Living Liver Donors
West China Hospital
Phase 2/3
60
Hefei, Beijing, Chengdu
2026-09-01
Not yet open
A Study to Learn About the Study Medicine Called PF-08653944 Taken Once-Weekly Compared to Placebo in Chinese Adults With Overweight or Obesity
NCT07792954Obesity, Overweight
Pfizer
Phase 3
300
Hefei, Beijing, Chongqing, Huizhou, Hengshui, Shijiazhuang, Harbin, Luoyang
2026-09-01
Recruiting
Efficacy and Safety of Telitacicept in the Treatment of Refractory Rheumatoid Arthritis
NCT07796516Difficult-to-treat Rheumatoid Arthritis, Rheumatoid Arthritis
Peking University People's Hospital
Phase 2
420
Hefei, Beijing, Chongqing, Quanzhou, Guangzhou, Jiangmen, Shenzhen, Nanning
2026-09-01
Recruiting
Transcranial Random Noise (tRNS) for BPSD in Alzheimer's Disease: A Double-blind Randomized Controlled Trial
NCT07827196Transcranial Random Noise Stimulation (tRNS), Electroencephalography, Alzheimer Disease, BPSD (Behavioral and Psychological Symptoms of Dementia)
Anhui Medical University
Not applicable
40
Hefei
2026-09-01
Not yet open
Effects of a Large Language Model-Driven Chatbot on Reproductive Concerns After Cancer
NCT07741266Chatbot, Large Language Model, Adolescent and Young Adult Cancer Survivors, Reproductive Health
The Hong Kong Polytechnic University
Not applicable
60
Hefei
2026-09-01
Recruiting
Glycoprotein IIb/IIIa PET/CT in Various GPIIb/IIIa-Related Disease
NCT07813559Thrombi, Thrombus, Brain, Thrombus
Tianjin Medical University
Observational
500
Hefei, Qingdao, Tianjin
2026-09-01
Not yet open
A Study of ATG-201 in Adult Participants With Autoimmune Diseases
NCT07732309Systemic Lupus Erythematosus, Systemic Sclerosis (SSc), Sjogren's Disease, Autoimmune Diseases
Antengene Biologics Limited
Phase 1
149
Bengbu, Hefei, Beijing, Xiamen, Guangzhou, Luoyang, Zhengzhou, Wuhan
2026-09-01
Not yet open
Clinical Trial of TQA3605 Tablet in Combination With Nucleos(t)Ide Analogues(NAs) Versus NAs Alone for the Treatment of Patients With Chronic Hepatitis B Virus Infection Who Have Undergone Treatment and Exhibit Low Viral Load or Poor Response
NCT07797231Chronic Hepatitis B
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
930
Hefei, Wuhu, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Wuwei
2026-09
Not yet open
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
NCT07794579Overweight, Prediabetic State, Prehypertension, Obesity, Abdominal
Eli Lilly and Company
Phase 3
2,001
Chengdu, Hefei, Jinan, Luoyang Shi, Nanjing, Ningbo, Qinhuangdao Shi, Tianjin
2026-09
Not yet open
Postoperative ctHPV-DNA for Recurrence Prediction and Adjuvant Treatment Decision-Making in Cervical Cancer
NCT07782697Cervical Cancer, HPV DNA
Anhui Provincial Hospital
Observational
580
Hefei
2026-09
Not yet open
Safety and Pharmacokinetics of HRS-1597 Tablets in Healthy and Obese Participants: A Phase 1 Study
NCT07808918Obese and Metabolic Disorders
Shandong Suncadia Medicine Co., Ltd.
Phase 1
78
Hefei
2026-09
Not yet open
Phase 3 Study to Evaluate the Efficacy and Safety of Human Growth Hormone Injection (Sinotropin AQ) for the Treatment of Children With Idiopathic Short Stature
NCT07815626Idiopathic Short Stature (ISS)
Zhongshan Sansure Hygene Biomedicine Co., Ltd.
Phase 3
240
Hefei, Beijing, Xiamen, Guangzhou, Tangshan, Wuhan, Changsha, Nanjing
2026-09
Not yet open
Study of SGC001 Injection for Predicted Severe Acute Pancreatitis to Assess Safety, Tolerability and Preliminary Efficacy
NCT07803965Acute Pancreatitis
Beijing Sungen Biomedical Technology Co., Ltd
Phase 2
129
Chengdu, Guizhou, Hangzhou, Hefei, Luoyang, Nanchang, Nanjing, Ningbo
2026-09
Not yet open
Development and Pilot Application of a Solution-Focused Intervention for Social Isolation in Elderly Diabetic Foot Patients
NCT07787884Diabetic Foot Disease
Anhui Medical University
Not applicable
70
Hefei
2026-08-27
Recruiting
A Clinical Trial of TQB6426 for Injection in Patients With Advanced Solid Tumors
NCT07730190Advanced Malignancies
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase 1
145
Hefei, Beijing, Fuzhou, Guangzhou, Harbin, Zhengzhou, Changsha, Shanghai
2026-08-25
Recruiting
AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications
NCT07797335Type 2 Diabetes, Cardiovascular Risk
Novo Nordisk A/S
Phase 3
1,778
Hefei, Beijing, Chongqing, Shenzhen, Cangzhou, Langfang, Shijiazhuang, Kaifeng
2026-08-24
Recruiting
A Study to Investigate the Efficacy and Safety of Elecoglipron in Asian Participants With Obesity or Overweight With or Without Type 2 Diabetes Mellitus
NCT07775404Obesity, Overweight
AstraZeneca
Phase 3
351
Baotou, Beijing, Changde, Changsha, Changzhou, Chengdu, Hefei, Huangshi
2026-08-21
Not yet open
Construction and Validation of a Coronary Artery Disease-Specific Large Language Model and Its Evaluation Framework (CorAI)
NCT07766551Coronary Heart Disease (CHD), Artifical Intelligence
China National Center for Cardiovascular Diseases
Observational
640
Hefei, Beijing, Shenzhen
2026-08-17
Not yet open
Effectiveness of an AI-Enabled Mobile Intervention on Lifestyle Behaviors and Maternal-Infant Health
NCT07582068Mobile Health Apps, Lifestyle Intervention, Prevention, Multi-component Based Behavioral Intervention
Fangbiao Tao
Not applicable
400
Hefei
2026-08-10
Not yet open
The Study is to Investigate D-2570 in Participants With Different Levels of Kidney Function.
NCT07715175Renal Impairment
InventisBio Co., Ltd
Phase 1
40
Hefei
2026-08-09
Recruiting
ctDNA-driven Adaptive Proton Craniospinal Irradiation in Non-Small Cell Lung Cancer With Leptomeningeal Metastasis After Resistance to Third-Generation TKIs in the Consolidation Phase
NCT07751536Leptomeningeal Metastasis From Lung Cancer
Shuanghu Yuan
Not applicable
84
Hefei, Nanjing
2026-08-05
Not yet open
Alpha-0261 Tablets for Moderate-to-Severe Ulcerative Colitis
NCT07744646Ulcerative Colitis (UC)
The First Affiliated Hospital of Anhui Medical University
Phase 1
10
Hefei
2026-08-03
Not yet open
Safety and Pharmacokinetics Study of Multiple Ascending Doses of VV261 Tablets
NCT07710326Healthy Volunteers
Vigonvita Life Sciences
Phase 1
16
Hefei
2026-08-01
Not yet open
A Study of LAE118 as Monotherapy and in Combination With Antitumor Agents in Advanced Solid Tumors
NCT07787520Patients With Advanced Solid Tumors
Laekna Limited
Phase 1
150
Hefei, Beijing, Changchun, Shanghai, Hangzhou
2026-08
Not yet open
A Phase I/II Open-label, Single-arm, Multicenter Clinical Study to Evaluate the Safety and Efficacy of FKC289 in Subjects With Relapsed/Refractory Membranous Nephropathy
NCT07765537Primary Membranous Nephropathy
Shenzhen Fosun Kairos Biotechnology Co., Ltd.
Phase 1/2
55
Hefei, Beijing, Guangzhou, Shenzhen, Wuhan, Changsha, Nanjing, Chengdu
2026-08
Not yet open
Phase III Study of OT202 in Treating Moderate to Severe Dry Eye
NCT07740564Dry Eye
Ocumension Therapeutics (Suzhou) Co., Ltd
Phase 3
842
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Shantou
2026-08
Recruiting
A Phase 2b Clinical Trial of YN001 in Adults With Coronary Atherosclerosis
NCT07521007Atherosclerosis, Coronary Artery Disease
Beijing Inno Medicine Co., Ltd.
Phase 2
456
Hefei, Beijing, Fuzhou, Lanzhou, Guangzhou, Harbin, Wuhan, Changsha
2026-07-31
Recruiting
A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis
NCT07497087Systemic Sclerosis
Boehringer Ingelheim
Phase 3
448
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Hefei, Luoyang
2026-07-27
Recruiting
Metronomic Oral Paclitaxel Plus PD-1/ PD-L1 Inhibitor Maintenance in Advanced Lung Cancer (PULSE Study)
NCT07744698Squamous Non-Small Cell Lung Cancer sqNSCLC, Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Anhui Provincial Cancer Hospital
Phase 4
107
Hefei
2026-07-24
Not yet open
AI-Assisted Lifestyle Intervention Versus Tirzepatide for Obesity and Newly Diagnosed Type 2 Diabetes
NCT07697391Obesity, Diabetes Mellitus, Type 2
The First Affiliated Hospital of Anhui Medical University
Phase 4
285
Hefei
2026-07-20
Not yet open
SMP-656 for HER2-Positive Advanced Breast Cancer
NCT07726342HER2-positive Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast Cancer (LABC)
Chengdu SciMount Pharmatech Co., Ltd.
Phase 2
60
Hefei, Beijing, Guangzhou, Shijiazhuang, Zhengzhou, Wuhan, Changsha, Nanjing
2026-07-16
Not yet open
Becotatug Vedotin Combined With Pucotenlimab ± Radiotherapy as First-Line Treatment for Driver-Gene-Negative, EGFR-Expression-Positive Advanced Non-Small Cell Lung Cancer
NCT07627321NSCLC (Advanced Non-small Cell Lung Cancer)
Anhui Provincial Cancer Hospital
Phase 2
39
Hefei
2026-07-15
Not yet open
JS212 in Combination With JS111 as First-Line Treatment in EGFR-Mutant Advanced NSCLC
NCT07714304NSCLC Harboring EGFR Mutations
Huan Zhou
Not applicable
20
Hefei, Shanghai
2026-07-13
Not yet open
A Phase II Study of H021 Enteric-coated Tablets for Moderately to Severely Active Crohn's Disease
NCT07677514Crohn's Disease
Jiangsu Carephar Pharmaceutical Co., Ltd.
Phase 2
156
Beijing, Bengbu, Changsha, Chongqing, Fujian, Guangzhou, Hefei, Huizhou
2026-07-12
Recruiting
A Study of MI078 for Postpartum Depression
NCT07721961Postpartum Depression (PPD)
Nanjing Minova Pharmaceutical Co., Ltd.
Phase 3
200
Hefei, Chongqing, Xiamen, Lanzhou, Guangzhou, Zhaoqing, Liuzhou, Guiyang
2026-07-10
Recruiting
A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus on Background Insulin
NCT07664553Type 2 Diabetes Mellitus
AstraZeneca
Phase 3
600
Changsha, Hefei, Huai'an, Langfang, Liangyugang, Luoyang, Nanjing, Nanyang
2026-07-08
Recruiting
A Study of BL-M07D1 Versus Physician's Choice of Chemotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Biliary Tract Cancer After Platinum-containing Chemotherapy Failure
NCT07606599Biliary Tract Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3
398
Hefei, Beijing
2026-07-07
Not yet open
A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of Intracerebral Injection of LY-N001 Injection for the Treatment of Moderate to Advanced Parkinson's Disease With GBA1 Mutations
NCT07685444Parkinson's Disease (PD)
Lingyi Biotech Co., Ltd.
Phase EARLY_PHASE1
18
Hefei
2026-07-07
Recruiting
A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus
NCT07662213Type 2 Diabetes Mellitus
AstraZeneca
Phase 3
1,200
Changsha, Hefei, Huai'an, Langfang, Liangyugang, Luoyang, Nanjing, Nanyang
2026-07-06
Recruiting
A Study to Evaluate the Effects of Enicepatide in Participants With Obesity or Overweight, With or Without Type 2 Diabetes
NCT07670416Obesity, Overweight, Type 2 Diabetes Mellitus (T2DM)
Hoffmann-La Roche
Phase 3
300
Zhengzhou, Xianyang, Ningbo, Beijing, Changchun, Hefei, Herbin, Huai'an
2026-07-03
Not yet open
Zishen Yutai Pill for Patients With Recurrent Implantation Failure
NCT07641088Recurrent Implantation Failure
Peking University Third Hospital
Not applicable
878
Hefei, Beijing, Guangzhou, Shijiazhuang, Zhengzhou, Changsha, Nanjing, Xi'an
2026-07-01
Not yet open
Finerenone in Patients Undergoing Transcatheter Aortic Valve Implantation With Heart Failure
NCT07575672HFpEF - Heart Failure With Preserved Ejection Fraction, TAVI(Transcatheter Aortic Valve Implantation), Finerenone
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 3
2,832
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Zhengzhou
2026-07-01
Not yet open
Red Dichromatic Imaging for Improving Post-Biopsy Bronchoscopic Field Visibility
NCT07653945Bronchoscopic Biopsy, Airway Lesion, Biopsy-related Bleeding
First Affiliated Hospital of Ningbo University
Observational
206
Hefei, Zhejiang, Shanghai
2026-07-01
Not yet open
The Impact of One-Year Boxing Training on Attention in Adolescent Athletes
NCT07688616Attention, Healthy Volunteers
Anhui Medical University
Not applicable
75
Hefei
2026-07-01
Not yet open
Network-Guided Individualized TMS for BPSD in Alzheimer's Disease: A Double-blind Randomized Controlled Trial
NCT07692542Transcranial Magnetic Stimulation, Behavioral and Psychological Symptoms in Alzheimer's Disease, Individualized Navigation
Anhui Medical University
Not applicable
40
Hefei
2026-07-01
Recruiting
Neoadjuvant RC48 Plus Gemcitabine in HER2-Expressing MIBC
NCT07693959MIBC
Zhiquan Hu
Phase 3
170
Hefei, Fuzhou, Xiamen, Guangzhou, Shenzhen, Enshi, Huanggang, Huangshi
2026-07-01
Not yet open
A Phase Ib/II Study of BM230 in Combination With PD-1 Inhibitor for HER2-related Advanced Solid Tumors
NCT07698587Solid Tumor
Suzhou Biomissile Pharmaceuticals Co., Ltd.
Phase 1/2
90
Hefei
2026-07
Not yet open
A Clinical Study of ZL-85FA Tablets
NCT07339748Advanced Solid Tumor
Chengdu Zenitar Biomedical Technology Co., Ltd
Phase 1/2
51
Hefei
2026-06-30
Not yet open
A Phase Ⅲ Clinical Study of SNA02-48 Injection
NCT07633119Tetanus
Sinovac Life Sciences Co., Ltd.
Phase 3
600
Fuyang, Hefei, Beijing, Guangzhou, Shenzhen, Liuzhou, Zunyi, Shijiazhuang
2026-06-28
Recruiting
Monoamine Oxidase A PET/CT in Various MAO-A-Related Disease
NCT07685860Depression, Anxiety, Heart Injuries
Tianjin Medical University
Observational
200
Hefei, Qingdao, Tianjin
2026-06-25
Recruiting
Monoamine Oxidase B PET/CT in Various MAO-B-Related Disease
NCT07685873Parkinson Disease, Parkinson Disease Dementia, Parkinson's Disease and Parkinsonism
Tianjin Medical University
Observational
200
Hefei, Qingdao, Tianjin
2026-06-25
Recruiting
A Study of AZD0292 in Chinese Participants With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization
NCT07774403Bronchiectasis With Pseudomonas Aeruginosa Colonization
AstraZeneca
Phase 2
84
Anyang, Beijing, Changsha, Chengdu, Chizhou, Haikou, Hefei, Hohhot
2026-06-24
Recruiting
Qishen Yiqi Dripping Pills in Treatment of Chronic Heart FailUre
NCT07687186Heart Failure
Tasly Pharmaceutical Group Co., Ltd
Phase 3
636
Bozhou, Hefei, Suzhou, Beijing, Fuzhou, Lanzhou, Qingyang, Dongguan
2026-06-22
Recruiting
Apheresis Collection for New Drug Development and Evaluation Research
NCT07663565PBMCs
TCRx Therapeutics Co.Ltd
Observational
200
Bengbu, Hefei
2026-06-22
Recruiting
Luvometinib in Pediatric SS-LCH With Special-site Single/Multifocal Bone Lesions
NCT07371182Langerhans Cell Histiocytosis (LCH)
West China Second University Hospital
Not applicable
62
Hefei, Nanning, Guiyang, Zunyi, Nanchang, Xi'an, Chengdu, Ürümqi
2026-06-19
Recruiting
A Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of TQ05105 Tablets in Subjects With Intermediate/High-risk Myelofibrosis
NCT07551427Myelofibrosis
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2
51
Hefei, Fuzhou, Guangzhou, Nanning, Cangzhou, Chengde, Shijiazhuang, Xingtai
2026-06-18
Recruiting
A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)
NCT07554339Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC
Phase 3
310
Hefei, Beijing, Xiamen, Nanning, Shijiazhuang, Wuhan, Changsha, Nanjing
2026-06-18
Recruiting
A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Subcutaneous UBT38006 Injection in Healthy Adult Males
NCT07630233Type 2 Diabetes Mellitus (T2DM)
The United Bio-Technology (Hengqin) Co., Ltd.
Phase 1
53
Hefei
2026-06-17
Recruiting
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
NCT07357727Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (PPV-MF), Post-essential Thrombocythemia Myelofibrosis (PET-MF)
Novartis Pharmaceuticals
Phase 3
460
Hefei, Guangzhou, Wuhan, Nanjing, Nantong, Changchun, Jinan, Yantai
2026-06-16
Not yet open
CS-121 APOC3 Base Editing in Severe Hypertriglyceridemia
NCT07657780Severe Hypertriglyceridemia (sHTG)
CorrectSequence Therapeutics Co., Ltd
Phase EARLY_PHASE1
15
Hefei
2026-06-15
Not yet open
GLP-1 Receptor Agonist in Primary Intracerebral Hemorrhage: A Phase 2 Randomized Trial
NCT07613437Intracerebral Hemorrhage
Chinese University of Hong Kong
Phase 2
200
Hefei, Wenzhou
2026-06-15
Active, closed
Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) as Prophylactic Treatment.
NCT07684898Severe Hemophilia A
Hangzhou Gensciences Biopharmaceutical Co., Ltd.
Phase 3
60
Tianjin, Fuyang, Fuzhou, Guangzhou, Hefei, Jinan, Kunming, Nanning
2026-06-12
Not yet open
Single-arm, Open-label, Dose-escalating Phase I Clinical Study of PA3-17 Injection in Children and Adolescents With Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma
NCT07623681CD7+ T-ALL/LBL
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Phase 1
12
Hefei
2026-06-10
Not yet open
A Prospective Study of Firmonertinib as First-line Adaptive Therapy Guided by Dynamic ctDNA (MRD) Changes in Locally Advanced or Metastatic EGFR-mutated Non-small Cell Lung Cancer
NCT07661173Non Small Cell Lung Cancer
Anhui Provincial Cancer Hospital
Phase 2
154
Hefei
2026-06-06
Recruiting
Anti-inflammatory Dietary Intervention in Patients With Type 2 Diabetes: A Randomized Controlled Trial
NCT07656805T2DM (Type 2 Diabetes Mellitus)
Anhui Medical University
Not applicable
88
Hefei
2026-06-03
Recruiting
Safety and Feasibility of the CorVad Percutaneous Ventricular Assist System in Refractory Right Heart Failure
NCT07704424Right Heart Failure
Shenzhen Core Medical Technology CO.,LTD.
Not applicable
6
Hefei, Beijing
2026-06-02
Not yet open
Super-Resolution Ultrasound Imaging for Assessing Response to Neoadjuvant Chemotherapy in Breast Cancer
NCT07623226Breast Cancer
Anhui Provincial Cancer Hospital
Observational
150
Hefei
2026-06-01
Rows per page Showing 1–100 of 875
1 2 3 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/hefei

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 875 of those studies with a site in Hefei.

How many clinical trials are recruiting in Hefei?

512 of the 875 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 137 have not yet opened recruitment, 211 are active but closed to new participants, and 15 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Hefei), 875 studies
PhaseStudiesRecruitingShare
Phase 329013033.1%
Phase 21378115.7%
Not applicable1198113.6%
Observational936310.6%
Phase 1925310.5%
Phase 1/266517.5%
Phase 427163.1%
Phase EARLY_PHASE126193%
Phase 2/325182.9%

Most active sponsors

Lead sponsors with the most studies (Hefei)
Lead sponsorStudiesRecruiting
Anhui Provincial Hospital5543
Merck Sharp & Dohme LLC3619
Anhui Medical University2914
AstraZeneca2715
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.2511
Eli Lilly and Company2412
Pfizer1810
Tianjin Medical University1717
Bristol-Myers Squibb166
The Second Hospital of Anhui Medical University1611
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.